PDSB stock forecast, quote, news & analysis
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more
Why PDS Biotechnology (PDSB) Stock Is Up +17% in the Last 30 Days
Key Takeaways
- PDSB shares have climbed roughly 17% over the past 30 days, from about $0.81 to near $0.95, in exceptionally volatile trading.
- The advance is anchored by a Nant Capital-led private placement and the addition of biotech entrepreneur Dr. Patrick Soon-Shiong to the board of directors.
- Investor attention has shifted to lead asset PDS0301, an IL-12 immunocytokine being advanced toward a Phase 3 trial in metastatic colorectal cancer.
- Over the trailing quarter the stock is up about 32%, though the period included a drawdown below $0.25 before the September rebound.
- Key risks remain dilution, a limited cash position, and execution uncertainty ahead of a planned registrational trial.
PDS Biotechnology (PDSB) Company Overview and Market Position
PDS Biotechnology is a clinical-stage immunotherapy company headquartered in Princeton, New Jersey, focused on developing targeted immunotherapies for cancer. Its lead program, PDS0301 (also referred to as PDS01ADC or NHS-IL12), is a tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment while limiting systemic exposure. The company is advancing PDS0301 in solid tumors, with a primary focus on microsatellite stable (MSS) metastatic colorectal cancer, an area where immunotherapy has historically shown limited benefit.
The company also owns the Versamune platform, including PDS0101, an HPV16-targeted immunotherapy evaluated in HPV16-positive cancers. As a pre-revenue, small-cap developer, PDSB is followed primarily for clinical data readouts, regulatory milestones, and financing events rather than traditional earnings fundamentals.
PDS Biotechnology (PDSB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PDSB has risen approximately 17.3%, moving from a closing level near $0.81 in mid-September to around $0.95. The advance has not been linear: the stock briefly traded above $1.60 in mid-October before pulling back, reflecting the stock's high volatility and thin, sentiment-driven trading.
The trailing-quarter picture is even more dramatic. From a closing level near $0.72 in late July, shares fell below $0.25 in August amid funding pressures, then surged on the September financing announcement and reached an intraday high above $1.75 in mid-October. On balance, the stock is up roughly 32% over the quarter, but the path has been marked by sharp swings in both directions.
What Drove PDSB Stock Price in the Last 30 Days
The dominant catalyst has been a strategic financing and the credibility it brought. In September, PDS Biotech closed the initial tranche of a Nant Capital-led private investment in public equity (PIPE) transaction of up to $22.3 million, raising roughly $11.3 million in gross proceeds. As part of the deal, Dr. Patrick Soon-Shiong, founder of NantWorks and executive chairman of ImmunityBio (IBRX), joined the board, and NantWorks received a one-year exclusive right to negotiate a license for PDS0101.
The financing directly addressed a pressing cash concern. The company had reported just $5.6 million in cash as of June 30 and used part of the proceeds to redeem a portion of outstanding debt. An additional $11 million contingent tranche is tied to the submission of a registrational Phase 3 protocol for PDS0301 to the U.S. FDA, giving investors a concrete milestone to watch.
Momentum was reinforced by clinical and corporate developments. Data from the Phase 2 VERSATILE-002 trial of PDS0101 in combination with pembrolizumab were published in JAMA Oncology, and an October key opinion leader event highlighted PDS0301 results in advanced colorectal cancer with liver metastases. The company also reshaped its board in mid-October, appointing three pharmaceutical-industry veterans while four directors resigned. A registration statement covering the resale of shares also reminded investors of potential dilution overhang.
What Drove PDSB Stock Performance Over the Last Quarter
The quarter's broader narrative is one of near-collapse followed by re-rating. Early in the period, shares traded down as the company faced funding constraints, announced a workforce reduction of about 36%, and reported a minimal cash balance. The August slide took the stock to its 52-week low before the September PIPE reset sentiment.
The Soon-Shiong investment was read by the market as validation of the PDS0301 platform, given his track record in oncology and his firm's existing portfolio. Analysts at H.C. Wainwright described the financing as a positive that reduced the funding overhang, while trimming their price target to $5 from $7 and maintaining a Buy rating. Interim Phase 2 data showing an 80% 24-month overall survival rate in advanced colorectal cancer has underpinned enthusiasm for the lead program, even as the company's contingent financing structure and diluted share count remain concerns.
Trending AI Robots
For investors looking to supplement their own research, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. Each bot varies in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than relying on a single model. The page is designed to help traders identify automated strategies that align with their own objectives. Exploring the selection can provide useful context for those following volatile names like PDSB.
PDSB Stock Forecast Drivers: What Investors Should Watch Next
Several milestones could shape PDSB going forward. The most important is the submission of a registrational Phase 3 protocol for PDS0301 to the FDA, which would trigger the additional $11 million financing tranche. Investors will also watch for updates on the planned Phase 3 trial in MSS metastatic colorectal cancer, additional PDS0301 clinical data, and any progress or decision on the NantWorks licensing option for PDS0101.
On the financial side, cash runway, potential further dilution from outstanding warrants and the registered resale of shares, and the company's ability to secure additional capital will remain central. Broader sentiment toward small-cap biotechnology and any macroeconomic shifts affecting risk appetite could also influence trading. These factors carry meaningful uncertainty, and outcomes will depend on execution rather than short-term price moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PDSB in upward trend: 10-day moving average broke above 50-day moving average on September 18, 2026
The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on September 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on PDSB as a result. In 70 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
Following a +35.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 78 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.105) is normal, around the industry mean (2.988). P/E Ratio (-1.938) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology